Shares of Hemostemix Inc. (CVE:HEM – Get Free Report) traded up 27.8% on Saturday . The company traded as high as C$0.12 and last traded at C$0.12. 335,071 shares traded hands during trading, a decline of 31% from the average session volume of 486,759 shares. The stock had previously closed at C$0.09.
Hemostemix Trading Up 27.8%
The company has a quick ratio of 0.48, a current ratio of 0.04 and a debt-to-equity ratio of -55.07. The business has a 50-day moving average of C$0.10 and a two-hundred day moving average of C$0.14. The firm has a market capitalization of C$16.76 million, a price-to-earnings ratio of -3.35 and a beta of 0.20.
Insider Buying and Selling at Hemostemix
In related news, Director Peter Alan Lacey acquired 200,000 shares of the firm’s stock in a transaction on Thursday, March 6th. The shares were bought at an average cost of C$0.15 per share, with a total value of C$30,000.00. Company insiders own 10.43% of the company’s stock.
About Hemostemix
Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia.
Read More
- Five stocks we like better than Hemostemix
- What Are Earnings Reports?
- Apple’s Quiet HomePad Delay Could Be Its Loudest Move Yet
- Do ETFs Pay Dividends? What You Need to Know
- e.l.f. Gets Back on the Shelf! It’s Not Too Late to Buy In!
- Why Understanding Call Option Volume is Essential to Successful Options Trading
- Near 52-Week Lows, These 3 Mid-Cap Stocks Are Worth a Look
Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.